Ken Griffin Merus N.V. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Merus N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 33,800 shares of MRUS stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,800

Previous 31,600 6.96%

Holding current value

$1.68 Million

Previous $1.42 Million 40.58%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$39.81 - $60.2 $6.78 Million - $10.3 Million	-170,355 Reduced 48.37%	181,853 $10.8 Million
Q1 2024 May 15, 2024	BUY	$28.03 - $51.82 $2.02 Million - $3.73 Million	71,957 Added 25.68%	352,208 $15.9 Million
Q4 2023 Feb 14, 2024	BUY	$20.06 - $28.66 $5.56 Million - $7.94 Million	277,066 Added 8699.09%	280,251 $7.71 Million
Q3 2023 Nov 14, 2023	SELL	$20.13 - $27.29 $1.67 Million - $2.27 Million	-83,099 Reduced 96.31%	3,185 $75,000
Q2 2023 Aug 14, 2023	SELL	$18.33 - $27.18 $1.08 Million - $1.61 Million	-59,175 Reduced 40.68%	86,284 $2.27 Million
Q1 2023 May 15, 2023	BUY	$14.25 - $20.5 $1.25 Million - $1.79 Million	87,533 Added 151.11%	145,459 $2.68 Million
Q4 2022 Feb 14, 2023	SELL	$12.8 - $23.66 $100,416 - $185,612	-7,845 Reduced 11.93%	57,926 $896,000
Q3 2022 Nov 14, 2022	BUY	$18.64 - $28.93 $926,631 - $1.44 Million	49,712 Added 309.56%	65,771 $1.32 Million
Q2 2022 Aug 15, 2022	SELL	$13.98 - $29.25 $9.26 Million - $19.4 Million	-662,676 Reduced 97.63%	16,059 $364,000
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $1.92 Million - $2.52 Million	81,393 Added 13.63%	678,735 $17.9 Million
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $8.38 Million - $13.5 Million	419,152 Added 235.23%	597,342 $19 Million
Q3 2021 Nov 15, 2021	SELL	$16.48 - $27.23 $584,150 - $965,194	-35,446 Reduced 16.59%	178,190 $3.92 Million
Q2 2021 Aug 16, 2021	BUY	$20.0 - $25.48 $3.26 Million - $4.15 Million	162,986 Added 321.79%	213,636 $4.5 Million
Q1 2021 May 17, 2021	BUY	$16.14 - $29.11 $817,491 - $1.47 Million	50,650 New	50,650 $1.06 Million
Q3 2020 Nov 16, 2020	SELL	$10.57 - $16.0 $217,372 - $329,040	-20,565 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$10.5 - $17.36 $215,932 - $357,008	20,565 New	20,565 $331,000

Others Institutions Holding MRUS

# of Institutions

188

Shares Held

59M

Call Options Held

345K

Put Options Held

222K

View Full List

About Merus N.V.

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

More about MRUS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account